What is Cholesterol? Forms of Cholesterol Heart Disease Symptoms of Heart Disease Heart Disease Prevention Heart Disease Precaution What are Statins? Cholesterol Medications Lipitor Lescol Mevacor Pravachol Crestor Zocor

July 2007 June 2007 May 2007 April 2007 March 2007 February 2007 January 2007 December 2006 November 2006

LipitorCare News » December 06

Statin Users Risk Heart Attacks by Stopping Treatment
07 Dec. 2006

People with high cholesterol levels who stop taking the drugs called statins increase their risk of heart attacks by at least 30 percent, a Dutch study finds.

And a lot of people do stop taking statins, which are prescribed to lower cholesterol in individuals at risk of coronary heart disease. More than half of the nearly 60,000 people followed in the study gave up on the drugs within two years, and only one-third were persistent users, taking a high or intermediate dose.

Hospital admissions for heart attacks fell by 30 percent among persistent users of the drugs. That finding is entirely understandable, said Ron Herings, director of the PHARMO Institute in Amsterdam, and an author of the report.

"You have a high risk when you start using these drugs," Herings said. "When you stop, your risk increases to baseline, and that is a 30 to 40 percent increase."

The reduction in risk was affected by how persistent people were in taking a statin and the dose they took, the study found. For example, the incidence of hospital admissions for people who took the drugs on a non-regular basis was reduced from 0.52 per 100 patient years to 0.42 per 100 patient years.

Among people using high or intermediate doses, the risk reduction was as high as 40 percent, while a low dose reduced the risk by only 20 percent.

"We need intensive therapy to get LDL cholesterol levels as low as possible," Nicholls said. LDL cholesterol is the bad kind that clogs arteries.

That fear goes against the clinical evidence indicating that statins are "the most rigorously tested class of drugs in terms of the number of patients enrolled in clinical trials," Nicholls said. Those trials show "statins are tolerated by the overwhelming majority of patients with no problems at all," he said.

As the Dutch study shows, "statins will remain an integral part of any strategy to reduce heart disease," Nicholls said.

Source:http://www.cbc.ca